News

Trial for next generation IMiD CC-122 opens for myeloma patients

A Phase I clinical trial investigating the safety and efficacy of a new drug, known as CC-122, has recently opened for relapsed and refractory myeloma patients. Made by Celgene, CC-122 is regarded as a next generation immunomodulatory (IMiD) drug which works by targeting the protein cereblon in a similar manner to the existing IMiDs thalidomide,…

Details

Kyprolis® combination launched in the UK for relapsed myeloma patients

Amgen has announced it has made Kyprolis (carfilzomib) available in the UK following the recent licensing approval by the European Commission. Kyprolis can now be used in combination with Revlimid and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The company is expected to resubmit a technology appraisal…

Details

Farydak® approved for myeloma patients in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients in Scotland. Patients who have received at least two previous lines of treatment, including a proteasome inhibitor and an immunomodulatory drug, now have the option of treatment with Farydak, a histone deacetylase inhibitor, in…

Details

EMA recommends Empliciti® as a treatment for relapsed myeloma

The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has granted a positive recommendation for the use of Empliciti (elotuzumab) as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The licensing application was based on data from the Phase III ELOQUENT-2…

Details

GWAS identifies locus linked to survival in myeloma

A study published recently in Nature Communications has identified a germline locus which is associated with survival in myeloma patients, indicating that inherited genotypes could provide prognostic information in addition to conventional tumour acquired prognostic factors. The research, performed at The Institute of Cancer Research (ICR) and funded by Myeloma UK, involved a meta-analysis of…

Details

MUK eight opens for recruitment

Myeloma UK is pleased to announce that MUK eight is the latest trial in the Myeloma UK Clinical Trial Network (CTN) to open to patient recruitment. MUK eight, a Phase II randomised trial, is comparing the safety and effectiveness of the oral proteasome inhibitor ixazomib in combination with cyclophosphamide and dexamethasone versus cyclophosphamide and dexamethasone alone in…

Details